Ligand Pharmaceuticals Inc (LGND)
116.55
+4.99
(+4.47%)
USD |
NASDAQ |
Nov 21, 16:00
116.89
+0.34
(+0.29%)
After-Hours: 20:00
Ligand Pharmaceuticals Enterprise Value: 1.983B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 1.983B |
| November 20, 2024 | 1.888B |
| November 19, 2024 | 1.893B |
| November 18, 2024 | 1.890B |
| November 15, 2024 | 1.891B |
| November 14, 2024 | 1.962B |
| November 13, 2024 | 2.087B |
| November 12, 2024 | 2.062B |
| November 11, 2024 | 2.113B |
| November 08, 2024 | 2.071B |
| November 07, 2024 | 2.235B |
| November 06, 2024 | 1.989B |
| November 05, 2024 | 1.880B |
| November 04, 2024 | 1.848B |
| November 01, 2024 | 1.845B |
| October 31, 2024 | 1.763B |
| October 30, 2024 | 1.840B |
| October 29, 2024 | 1.948B |
| October 28, 2024 | 1.907B |
| October 25, 2024 | 1.878B |
| October 24, 2024 | 1.863B |
| October 23, 2024 | 1.786B |
| October 22, 2024 | 1.778B |
| October 21, 2024 | 1.784B |
| October 18, 2024 | 1.776B |
| Date | Value |
|---|---|
| October 17, 2024 | 1.767B |
| October 16, 2024 | 1.791B |
| October 15, 2024 | 1.739B |
| October 14, 2024 | 1.721B |
| October 11, 2024 | 1.712B |
| October 10, 2024 | 1.662B |
| October 09, 2024 | 1.717B |
| October 08, 2024 | 1.712B |
| October 07, 2024 | 1.706B |
| October 04, 2024 | 1.746B |
| October 03, 2024 | 1.698B |
| October 02, 2024 | 1.655B |
| October 01, 2024 | 1.682B |
| September 30, 2024 | 1.658B |
| September 27, 2024 | 1.552B |
| September 26, 2024 | 1.589B |
| September 25, 2024 | 1.578B |
| September 24, 2024 | 1.592B |
| September 23, 2024 | 1.594B |
| September 20, 2024 | 1.651B |
| September 19, 2024 | 1.691B |
| September 18, 2024 | 1.667B |
| September 17, 2024 | 1.678B |
| September 16, 2024 | 1.691B |
| September 13, 2024 | 1.687B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
244.02M
Minimum
Mar 16 2020
2.271B
Maximum
Feb 09 2021
1.105B
Average
1.074B
Median
Jan 17 2024
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals Inc | 74.00B |
| Agios Pharmaceuticals Inc | 2.163B |
| ADMA Biologics Inc | 5.050B |
| Pieris Pharmaceuticals Inc | 1.673M |
| AnaptysBio Inc | 214.06M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.172M |
| Revenue (Quarterly) | 51.81M |
| Total Expenses (Quarterly) | 40.86M |
| EPS Diluted (Quarterly) | -0.39 |
| Gross Profit Margin (Quarterly) | 95.27% |
| Profit Margin (Quarterly) | -13.84% |
| Earnings Yield | 2.15% |
| Operating Earnings Yield | 0.85% |
| Normalized Earnings Yield | -0.7195 |